Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study

Emma Wilson, Tricia McKeever, Beverley Hargadon, Glenn Hearson, John Anderson, David Hodgson, Helen Bailey, Garry Meakin, Mike Thomas, Ian D. Pavord, Tim Harrison, Dominick Shaw
European Respiratory Journal 2014 44: 1705-1707; DOI: 10.1183/09031936.00093614
Emma Wilson
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tricia McKeever
2Dept of Epidemiology and Public Health, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beverley Hargadon
3Institute for Lung Health, Glenfield Hospital, Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn Hearson
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Anderson
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Hodgson
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Bailey
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garry Meakin
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Thomas
4Dept of Primary Care, University of Southampton, Southampton, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian D. Pavord
5University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Harrison
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominick Shaw
1Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dominic.shaw@nottingham.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Inhaled corticosteroids (ICS) reduce airway inflammation; however, guidelines recommend titrating ICS dose based on symptoms [1], which are not closely associated with airway inflammation [2]. Once symptoms are controlled for ≥3 months, ICS reduction is recommended [3] but step-down is often not implemented. Studies suggest that the majority of patients treated with ICS can have their therapy stepped down, although there is no clear evidence on how best to achieve this [4].

We assessed whether exhaled nitric oxide fraction (FeNO) measurements could predict a loss of symptom control or exacerbation following a reduction in ICS dose in a cohort study of people with well-controlled asthma recruited from primary care.

All participants had a recorded asthma diagnosis, were aged 18–75 years, and had received at least one ICS prescription in the last year. The study was restricted to nonsmokers (<10 pack-years). Poorly compliant participants, and participants with an asthma exacerbation requiring oral steroids in the previous 12 weeks or with a Juniper five-item Asthma Control Questionnaire (ACQ-5) [5] score >1.5 at visit 1 (indicating poor control) were excluded.

Participants were seen at the same time of day on four occasions: days 0, 14, 21 and 110. At each visit, ACQ-5, FeNO (Flex Flow; Aerocrine, Solna, Sweden) and spirometry were performed. Symptoms were assessed using the ACQ-5 [6]. Airway inflammation was measured using FeNO at 50 mL·s−1; participants were blinded to their measurements. Differential cell counts were performed on induced sputum. Spirometry was performed. Airway hyperresponsiveness was assessed using the concentration of methacholine required to provoke a 20% fall in forced expiratory volume in 1 s (PC20). Differential blood eosinophil count and IgE measurement were performed.

Participants were re-assessed at visit 2; if their ACQ-5 score remained <1.5 and had not increased by >0.5, their ICS dose was reduced by 50%. Inhaler types were kept the same. Participants were asked to take the half dose of ICS for 7 days and then return for visit 3. At visit 3, the ACQ-5 score was re-measured.

A loss of control was defined as an increase in ACQ-5 score >0.5 (the minimal important difference in asthma control [7]). An exacerbation was defined as increasing asthma symptoms requiring a course of antibiotics or oral steroids [8]. All participants who contacted the emergency team were assessed by a physician within 24 h and their ACQ-5 recorded; decisions on treatment were based on British Thoracic Society guidelines.

We estimated that 154 subjects would provide 80% power to show that a low FeNO or lack of change in FeNO following ICS reduction could successfully predict stable control [8, 9]. Data were analysed in two ways: firstly, we assessed whether a low baseline FeNO predicted successful ICS dose reduction; secondly, we evaluated whether an increase in FeNO following dose reduction predicted deterioration. We also evaluated whether other clinical measures predicted successful dose reduction at 3 months. Measures included: spirometry; methacholine PC20; IgE; blood eosinophil count; ACQ-5; and differential sputum eosinophil and neutrophil count.

191 participants had their FeNO level measured at before (visit 2) and 7 days after (visit 3) a 50% reduction in ICS dose (visit 3) (table 1). 128 (67%) participants completed the 3-month study period (after ICS reduction) with no loss of control or exacerbation, and 63 (33%) out of 191 experienced either a loss of control (n=32, 17%) or exacerbation (n=31, 16%). The median (interquartile range) baseline ACQ-5 was 0.6 (0.2–1.0) for the stable group and 0.8 (0.2–1.0) for the deterioration group (p=0.53). The mean±sd ICS beclomethasone dipropionate (BDP)-equivalent dose reduction across the study was 363±267 μg.

View this table:
  • View inline
  • View popup
Table 1– Baseline demographics presented for study population#

There were no significant differences in baseline FeNO (visit 2) between those successfully reducing ICS dose and those suffering from a loss of control or exacerbation. At 50 mL·s−1, the geometric mean baseline FeNO was 18.9 ppb (95% CI 16.8–21.5 ppb) in the stable group and 19.7 ppb (95% CI 16.4–23.6 ppb) in the deterioration group (p=0.76).

There was no significant difference in the change in FeNO in the week following ICS reduction (visit 2 to visit 3) between the stable and deterioration groups. The mean±sd absolute change between visit 2 and 3 was 1.58±11.9 ppb for the stable group and 1.03±14.88 ppb for the deterioration group (p=0.80). There were no significant differences in any of the clinical measurements between groups.

Although guidelines recommend a 50% reduction in ICS dose after 3 months of good symptom control, there is evidence of overtreatment with ICS [10] and a reluctance to reduce treatment [11]. Consequently, using inflammometry to guide treatment decisions may be beneficial. We addressed previous criticisms by evaluating both individual baseline FeNO and change from baseline. Neither baseline FeNO measurements nor change at 7 days following ICS dose reduction could predict which participants would remain stable or lose control over the next 3 months.

Participants were not blinded to their treatment allocation and a period of 7 days was used after step-down before repeating the FeNO measurements. This design was chosen to reflect real-life practice and for maximum future practical benefit. A 50% reduction was chosen as it is consistent with guideline recommendations. Our study was well powered to identify any change in FeNO values: the relationship between sputum eosinophilia and FeNO levels is strongest between 100 and 800 μg ICS (BDP equivalent) [12]; previous studies have shown that ICS dose reductions less than the mean reduction in our study result in an increase in FeNO levels [13]; dose-dependent onset and cessation of action effects of ICS on FeNO levels have been demonstrated, with levels rising after one day of treatment reduction [14]; and the largest change in FeNO values is found at 400 μg BDP [15], the mean value in our population.

The lack of change in FeNO following dose reduction may reflect that: 1) FeNO measurements do not correlate well enough with airway inflammation in mild-to-moderate asthma; 2) ICS dose reduction was not large enough; and 3) the episodes of loss of control were not due to increased airway inflammation.

In addition to the failure to predict ICS reduction using FeNO, we found that none of the baseline clinical indices (induced sputum, methacholine responsiveness and spirometry) had predictive value for future stability following ICS step-down. This has important implications for ICS dose reduction and suggests better methods of identification of those at risk of a loss of control following ICS dose reduction are needed.

Footnotes

  • Clinical trial: This study is registered at www.clinicaltrials.gov with identifier number NCT01308411.

  • Support statement: The study was funded by a grant from the UK National Institute for Health Research (NIHR). This paper presents independent research funded by the NIHR under its Research for Patient Benefit Programme (grant reference number PB-PG-1208-18175). The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR or the UK Department of Health. The NIHR had no role in study design, or collection, analysis and interpretation of data; or in the writing of the report; or in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.

  • Conflict of interest: None declared.

  • Received March 24, 2014.
  • Accepted July 24, 2014.
  • ©ERS 2014

References

  1. ↵
    British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. A national clinical guideline. 2012 (revision). London, BTS, 2012.
  2. ↵
    1. Shaw D,
    2. Green R,
    3. Berry M,
    4. et al
    . A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. Prim Care Respir J 2012; 21: 283–287.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Papi A,
    2. Nicolini G,
    3. Crimi N,
    4. et al
    . Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. Respir Res 2012; 13: 54.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Rank MA,
    2. Hagan JB,
    3. Park MA,
    4. et al
    . The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131: 724–729.
    OpenUrlCrossRefWeb of Science
  5. ↵
    1. Juniper EF,
    2. Svensson K,
    3. Mork AC,
    4. et al
    . Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553–558.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Juniper EF,
    2. O’Byrne PM,
    3. Guyatt GH,
    4. et al
    . Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902–907.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Juniper EF,
    2. Bousquet J,
    3. Abetz L,
    4. et al
    . Identifying “well-controlled” and “not well-controlled” asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616–621.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Shaw DE,
    2. Berry MA,
    3. Thomas M,
    4. et al
    . The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176: 231–237.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Tattersfield AE,
    2. Postma DS,
    3. Barnes PJ,
    4. et al
    . Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160: 594–599.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Diette GB,
    2. Patino CM,
    3. Merriman B,
    4. et al
    . Patient factors that physicians use to assign asthma treatment. Arch Intern Med 2007; 167: 1360–1366.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Hewitt RS,
    2. Modrich CM,
    3. Cowan JO,
    4. et al
    . Outcomes using exhaled nitric oxide measurements as an adjunct to primary care asthma management. Prim Care Respir J 2009; 18: 320–327.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Silkoff PE,
    2. McClean P,
    3. Spino M,
    4. et al
    . Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001; 119: 1322–1328.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Kharitonov SA,
    2. Yates DH,
    3. Chung KF,
    4. et al
    . Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 1996; 9: 196–201.
    OpenUrlAbstract
  14. ↵
    1. Kharitonov SA,
    2. Donnelly LE,
    3. Montuschi P,
    4. et al
    . Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002; 57: 889–896.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Jatakanon A,
    2. Kharitonov S,
    3. Lim S,
    4. et al
    . Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54: 108–114.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 44 Issue 6 Table of Contents
  • Table of Contents
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study
Emma Wilson, Tricia McKeever, Beverley Hargadon, Glenn Hearson, John Anderson, David Hodgson, Helen Bailey, Garry Meakin, Mike Thomas, Ian D. Pavord, Tim Harrison, Dominick Shaw
European Respiratory Journal Dec 2014, 44 (6) 1705-1707; DOI: 10.1183/09031936.00093614

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study
Emma Wilson, Tricia McKeever, Beverley Hargadon, Glenn Hearson, John Anderson, David Hodgson, Helen Bailey, Garry Meakin, Mike Thomas, Ian D. Pavord, Tim Harrison, Dominick Shaw
European Respiratory Journal Dec 2014, 44 (6) 1705-1707; DOI: 10.1183/09031936.00093614
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society